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One Hundred Ten Consecutive Primary Orthotopic Liver Transplants 
Under FK 506 in Adults 
S. Todo. J.J. Fung, A. Tzakis. A.J. Demetris, A. Jain, M. Alessiani, S. Takaya. A. Day, A. Gordon. and 
T.E. Starzl 
FK 506 was introduced clinically as salvage therapy for patients with failing liver graftsKfK~ Then in August 
1989. a trial was started in which FK 506 was used as the 
primary immunosuppressant in fresh cases. combined with 
steroids. from the time of hepatic transplantation. J.4 From 
then until mid-February 1990. 125 consecutive recipients 
entered the trial. of whom 110 were adults and 15 were 
children. This phase of the drug's development came to an 
end with the institution of a randomized trial in mid-
February 1990. The results as of 1 April 1990 in all but 5 of 
these cases were previously reponed. 4 Funher follow·up 
of the pediatric case collection is being provided at this 
meeting by Tzakis et al. 5 We will account here for all of the 
original 110 adult liver recipients. Because follow-ups are 
to 15 August 1990. the observation period in surviving 
patients ranges from 6 months to I year. 
METHODS 
Case Matenal 
The features of the 110 adult recipients are summarized in Table I. 
These were similar to those in 325 consecutive adults treated with 
conventional immunosuppression from October 198; to Novem-
ber 1988. except that there appeared to have been a higher 
representation recently of sicker candidates as reflected by the 
UNOS urgency classification. 
The treatment protocol of FK S06 has been descnbed in more 
detail previously," Intravenous therapy was star1ed at 0,15 mgi 
kg/d (in divided dosest. and oral dosmg was begun at 0.3 mg.;kg/d. 
also in divided doses. as soon as alimentallon was possible, These 
Table 1. Cases Receiving Consecutlve Orthotopic Uver Trans-
plantation Under the Treatment with FK ~ 01' Cyclosportne 
FK506 eyA 
N 110 325 
Age 46 (1&-70) 46 (1&-73) 
Malellemale 58152 1781147 
Indication ("!o) 
Parenchymal 72 (65) 192 (58) 
Cholestatic 28 (25) 81 (25) 
Metabolic 5 (51 8 (3) 
Malignant 3 (31 25 (8) 
Others 
UNOS score ("!o) 
2 (21 19 (61 
1 0 19 (6) 
2 25 (23) 61 (19) 
3 43 (39) 160 (49) 
4 15 (14) 48 (15) 
4US 27 (25) 37 (11) 
'F!( S06 from AugwI 1988 10 Feen.y 1989. 01 cycJoIpai •• from Octobar 
1987 10 Novemoer 1911. 
doses are still undergoing revision and cannot N: considered final. 
as has been discussed else\\, here at this conference.6 In the first 
half of the series. a I g bolus of prednisone \\, as given intraoper-
atively. as well as a 5-day burst of prednisone beginning with 200 
mg on the first postoperati,'e day and cnding \\'lth 20 mg.:d on the 
6th day. In the last pan of the series. daily maintenance with 20 
mg/d prednisone was used from the outset. Patients with rejection 
were treated as needed with augmentation of the FK 506 doses 
and/or maintenance steroid doses. I g of hydrocor1isone or 
methylprednisolone. a 3· to 5-<1ay course of 5 mg'd of OKT3. or in 
a few cases by the addition of azathioprine. Management was 
facilitated by protocol biopsies after approximately::! postopera-
tive weeks. and again al 2 months. Additional t-iopsies were taken 
for speCific indications. 
RESULTS 
Patient and Graft Survival 
Eight (7.3%) of the patients have died. leaving an actual 
survival of 9OKT~ after 6 to 12 months. The actuarial 
survival at I year is projected at 9~ <Fig 1). which 
compares favorably with historical controls. Of the 102 
survivors. 96 bear their original grafts. whereas 6 an: 
surviving by virtue of a second (3 examples) or third graft 
(3 examples). 
Retransplantation Rate 
The consumption of grafts to treat these 110 patients was 
124. meaning that the retransplant rate within 6 to 12 
months was 1OKT~K One hundred of the 110 patients were 
given a single graft. 6 were provided with two organs. and 
4 patients had three organs. The factors necessitating 
retransplantation are summarized in Fig 2. Primary graft 
nonfunction. technical accidents. and rejection were the 
principal reasons for retransplantation. This profile was 
similar to that in the preceding era using conventional 
immunosuppression. although the absolute incidence was 
smaller in the FK .506 historical controls. As in the pasl. 
the need for retransplantation carried a degraded progno-
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Fig 1. Patient survival curves in 110 consecutive adutt liver 
recipients treated with FK 506. and 325 historical controls under 
conventJonal immunosuppressllf1~ Both series were consecutive. 
without C!.Jlling for any reason including technical misadventures or 
primary graft dysfunction. 
sis. Of the 10 patients who carne to retransplantation 
during the 6- to 12-month follow-up period. only 6 (60%) 
surviVed. 
Causes 01 Death 
The causes of mortality in the whole series is summarized 
in Fig 3. In both the past and current experience. some of 
the deaths were caused by irreversible preexisting compli-
cations (for example. brain injury with fulminant hepatic 
failure). technical errors at the time of this complex 
operation. primary nonfunction of grafts. strokes. and 
heart failure. The principal improvement in mortality com-
pared to the past was a reduction in complications of lethal 
infections (Fig 3). 
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FIg 2. Incidence and cause of retrBns!:llantation within 6 months 
in FK 506 patients and in historical controls under conventional 
immullOSlJPPl'ession. 
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rig 3. The incidence and cause of patient death in the first 6 
months in the FK 506 patients and historical control patients 
treated With conventional Immunosuppression. There have been 
no further deaths in the FK 506 patients. all of whom have been 
followed from 6 to 1 2 months. 
Indices 01 Immunosuppression 
Treatment during the first postoperative month with agents 
other than FK 506 and cyclosporine (eyA) is summarized 
in Fig 4 for the current and historical series. The amount of 
prednisone used for either bolus or maintenance treatment 
v'-as greatly reduced in the FK 506 patients as was the 
administration of OKT3 and azathioprine. At the same 
time. the clinical diagnosis of rejection was made less 
frequently (Fag 4). 
The steroid sparing was even more obvious as the 
months went by (Fig 5). Within 2 months. 45% of the FK 
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F1g 4. Other inmunosuppressive agents used during the first 
pos:IOperative month in all 110 adult patients treated with FK 506. 
~ to 243 historical control patients. Culled from the control 
~ were recipients with catastrophic early courses. or those for 
whom information was incomplete because of early death andlor 
ilCugll~ data retrieval. 
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FIg 5. Average daily prednisone doses during the first 9 months. 
The data for the FK 506 and histonc:aJ cases are complete out to 
6 months. but partial for the 9·rnonttl FK 506 case entries since 
some of the later patients have ncx reached 9 months. 
506-treated patients were off steroids and throughout the 
first half-year further average reductions were possible 
(Fig 5). 
The average FK 506 doses and plasma levels are shown 
in Fig 6. The starling IV dose was converted to the oral 
route in 90% of the cases within the first week. The plasma 
FK 506 levels were higher during the first 2 weeks than at 
any time later. After the patients were stable. the mainte-
nance FK 506 levels were highly variable. and between I 
and 9 months there was no correlation in the plasma levels 
and the doses being given at the time of plasma testing (Fig 
7). 
In separate studies. the overriding effect of hepatic 
dysfunction on FK 506 pharmacokinetics has been de-
scribed in detail."·' In essence. the conclusion was that 
hepatic dysfunction disposed patients to overdosage when 
hepatic elimination was impaired. leading to toxicity and 
the need for highly individualized management. Because 
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FIg 8. Oaily doses of FK 506 in all 110 patienls. Note the 
tendency of plasma FK 5061eW'8is to be high early poesacperatively. 
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Fig 7. Altho\.ql the doses and plasma FK 506 levels seem 
parallel in Fig 7. the correlatJon of doses and plasma levets in 
individual cases had no relatIOnShip. 
of this. the patients herein reported were stratified into 96 
who had extended survival with relatively uncomplicated 
courses and 14 who recei .. ed compromised grafts or failed 
to achieve good graft fun.-:tion for other reasons (Fig 8). 
After the perioperative period. those with smooth courses 
had very sta~e FK 506 doses and plasma levels with good 
liver graft function. and Iinle or no permanent increase in 
serum creatinine. In contr.lst. the so-called compromised 
patients had higher and more volatile plasma FK 506 levels 
and concomitant significant elevations in serum creatinine 
(Fig 8). 
Liver Functioo 
The standard liver fun ... "tion tests in the foregoing 96 
patients who were culled and stratified to the satisfactory 
group were i:ompared to the best Cy A cases. Culling of the 
325 historical cases was more extensive. because there 
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Table 2. Ca ... Used for the Comparison of He\)atlc and Renal 
function Between FK 506 and Cyclospoline' 
FK506 CVA 
N 110 325 
PrimaryOLTx 
n 100 259 
Alive 96(87.3%) 193(59.4%) 
Died 4 66 
Multiple OLTx 
n 10 66 
Alive 6 31 
Died 4 35 
'FoIlowup period was 6-12 monttls in FK group. and 12 rnaI'IChs in C'fdOSI)OI'In8 
group. 
were greater numbers of patients with early death or very 
difficult convalescence; 1321325 (40.6%) were eliminated. 
leaving 193 (Table 2). 
The results of liver function in the current vs historical 
"clean" cases are shown in Figs 9-12 and showed no 
difference in the mean bilirubin. SOOT. SOPT. and gamma 
OTP values. 
Renal Function 
A significant rise in renal function during the first 5 
postoperative months in the II compromised FK 506 
recipients is shown in Fig 7. In the favorable FK 506 and 
historical series, there was no significant difference either 
in the earty or late serum creatinine or BUN values. 
although there was a transient early increase in both (Figs 
13. 14). 
The patients treated with FK 506 had a low incidence of 
arterial hypenension (Fig (5). At the end of 6 months. only 
22% were receiving some kind of antihypenensive medi-
cation. in almost all instances with a single drug. Many of 
these patients were hypenensive preoperatively. McCau-
ley et al8 are reporting a complete analysis of these cases 
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Fig t. Average serum bilirubin concentrations in the 96 FK 506 
patients with smooch courses shown in Fig 8. in comparison to the 
bilirubins in 193 similar patients treated with a cydosporine-
containing regimen. 
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FIg 10. SGOT values in same comparison as in Fig 9. 
elsewhere at this meeting \\.ith spe1:iai focus on those who 
had continuous function of their first liver graft. 
Other Measurements 
The serum cholesterol values became stable at a normal 
range within 2 months (Fig 16). There was no identifiable 
upward drift. Uric acid values were normal initially. but 
with a tendency for a later average increase. The signifi-
cance of these findings is under study. 
DISCUSSION 
The information reponed herein was similar to that in an 
eartier repon4 but with 4s~ months longer follow-up. What 
has accrued is further evidence of the feasibility and safety 
of both acute and chronic treatment with FK 506. No 
patient entered into the study has been removed from it. 
With follow-up of 6 to 12 months. we are able to project 
accurately that patient survi"a1 will be at 90% or higher 
with the graft survival not far behind. This has been better 
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FIg 12. Serum gamma glutarryl tra"sceptidase (S-GGTP) in 
same comparison as in Fig 9. 
than we were able to achieve pren)usly with the same or 
more favorable case mix. 
The incidence of nephrlloxici~ and other side effects 
has been acceptable. and large!) confined to patients 
(about 11% of the total) who were classified as compro-
mised by poor hepatic graft funaion. or by catastrophic 
technical or metabolic complicatio..'"'ls. A relative freedom 
from arterial hypel1ension was nOlewol1hy under FK 506. 
The general characteristics of the 5urviving patient popu-
lation in terms of liver function WC'e no different from that 
in patients who had a smooth recO\ery under CyA. but this 
was achieved with very low steroid requirements. 
These results were from a pilot rrial in which no prelim-
inary groping for the optimal m:magement policies was 
inyolved. and. consequentl~K e\C'Y case of primary liver 
transplantation induding the firSl. one contributed to the 
series. As discussed elsew~reKtc - the induction doses of 
FK 506 may have been higher thai:: necessary or desirable. 
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FIg 13. Average serum crealinine values in the FK 506 and 
cydosporine patients shown in Fig t. 
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rig 14. AVe-3ge blood urea nitrogen values (BUN) in the;;;'o( 506 
and cyctospcrne patients shown in Fig 9. 
particularly if good immediate graft function "15 not 
achieved. However. what was learned justifies ~~rther 
examination of this drug's potential. not only i= liver 
transplantation but also in transplantation of other Jrgans 
and for nontransplant indications. 
There can be little argument against the next oge of 
randomized trials on grounds that FK 506 ma~ De an 
inferior drl!2. Rather. the ethical dilemma could =e the 
obverse. tl-";t there is considerable evidence alrea:y that 
FK 506 reglmens provide the best chance for ;:atient 
survivaL The dilemma has been made particular::- trou-
bling by ltlt demonstration that FK 506 can be uRMKK~ as a 
court of las: appeal in liver and heart recipients. Ilo'len all 
other cOO\ <!ntional approaches have already failec. .. ::.H 
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FIg 15. Need for antihypertensive in 102 patients wt'C survived 
for the first 6 months under FK 506 ilTll'llUl'lOSUPressiOn. Almost all 
of those receMng an hypertensive medication wef8 rx: a single 
drug. 
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Fig 16. The course of 5e'1JrTl cholesterol and uric acid levels after 
liver transplantation unCle- A< 506. 
SUMMARY 
An account is giyen coi the 6- to 12-month survival. and 
causes of failure in I IO consecutive patients who Un.ler-
went primary liver tr..:.nsplantation under treatment from 
the outset with FK 506 and steroids. The patient survival is 
92.7%, and the first gr-d't survival is 87.3%. At a very high 
frequency, the patients achieved good graft function. and 
they had a relatively low morbidity that was pania1ly 
TODO. FUNG. TZAKIS ET AL 
ascribable to minimal use and early discontinuance (in 60% 
of cases) of steroids. Renal dysfunction and other adverse 
findings were largely confined to patients with poor initial 
graft function and .::onsequent apparent alteration of the 
kinetics of FK 506 elimination. causing functional overdos-
age. Results compare very favorably with our past record 
using conventional immunosuppression. and support the 
belief that FK 506 is a superior immunosuppressive agent 
which is suitable fL'\f chronic administration. 
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